levodopa has been researched along with naphthoquinones in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azulay, JP; Benel, L; Boraud, T; Chaigneau, V; Cormier-Dequaire, F; Corvol, JC; Debilly, B; Dellapina, E; Durif, F; Eusebio, A; Galitzky, M; Guimarães-Costa, R; Haddad, R; Houot, M; Lacomblez, L; Mariani, LL; Meissner, WG; Rascol, O; Salis, A; Thalamas, C | 1 |
| Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, IB; Park, HY; Ryu, YK | 1 |
1 trial(s) available for levodopa and naphthoquinones
| Article | Year |
|---|---|
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naphthoquinones; Parkinson Disease; Treatment Outcome | 2019 |
1 other study(ies) available for levodopa and naphthoquinones
| Article | Year |
|---|---|
β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease.
Topics: Animals; Dyskinesias; Levodopa; Male; Mice; Naphthoquinones; Oxidopamine; Parkinson Disease, Secondary | 2021 |